Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPR NASDAQ:CHEK NASDAQ:DRCT NASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$6.04-5.0%$7.39$4.35▼$23.40$276.13M0.731.93 million shs1.26 million shsCHEKCheck-Cap$2.12+184.2%$0.70$0.56▼$3.13$12.40M0.191.18 million shs128.17 million shsDRCTDirect Digital$0.42-0.5%$0.49$0.38▼$6.59$9.41M6.011.03 million shs107,114 shsSLGLSol-Gel Technologies$23.96-3.4%$16.04$4.01▼$30.00$66.83M1.2523,785 shs6,565 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics0.00%-5.64%-20.10%-48.63%+38.56%CHEKCheck-Cap0.00%+11.33%+12.17%-0.55%-58.33%DRCTDirect Digital0.00%-3.49%+2.44%-20.92%-83.33%SLGLSol-Gel Technologies0.00%-11.93%+59.49%+240.83%+297.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$6.04-5.0%$7.39$4.35▼$23.40$276.13M0.731.93 million shs1.26 million shsCHEKCheck-Cap$2.12+184.2%$0.70$0.56▼$3.13$12.40M0.191.18 million shs128.17 million shsDRCTDirect Digital$0.42-0.5%$0.49$0.38▼$6.59$9.41M6.011.03 million shs107,114 shsSLGLSol-Gel Technologies$23.96-3.4%$16.04$4.01▼$30.00$66.83M1.2523,785 shs6,565 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics0.00%-5.64%-20.10%-48.63%+38.56%CHEKCheck-Cap0.00%+11.33%+12.17%-0.55%-58.33%DRCTDirect Digital0.00%-3.49%+2.44%-20.92%-83.33%SLGLSol-Gel Technologies0.00%-11.93%+59.49%+240.83%+297.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics 3.11Buy$22.56266.88% UpsideCHEKCheck-Cap 0.00N/AN/AN/ADRCTDirect Digital 2.50Moderate Buy$6.001,338.85% UpsideSLGLSol-Gel Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SLGL, CHEK, DRCT, and CAPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/8/2025DRCTDirect DigitalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/14/2025CAPRCapricor TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/14/2025CAPRCapricor TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$31.00 ➝ $12.007/11/2025CAPRCapricor TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.007/11/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$77.00 ➝ $24.006/30/2025CAPRCapricor TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.006/26/2025CAPRCapricor TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.006/25/2025CAPRCapricor TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/25/2025CAPRCapricor TherapeuticsJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $29.006/24/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$77.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$13.39M20.99N/AN/A$3.20 per share1.92CHEKCheck-CapN/AN/AN/AN/A($0.25) per shareN/ADRCTDirect Digital$62.29M0.15N/AN/A($1.21) per share-0.34SLGLSol-Gel Technologies$11.54M5.84N/AN/A$10.36 per share2.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$40.47M-$1.64N/AN/AN/A-181.71%-62.71%-50.82%11/12/2025 (Estimated)CHEKCheck-Cap-$25.15M-$3.00N/A∞N/AN/AN/AN/AN/ADRCTDirect Digital-$6.24M-$1.83N/AN/AN/A-25.99%N/A-36.29%11/11/2025 (Estimated)SLGLSol-Gel Technologies-$10.58M-$1.23N/AN/AN/A-14.25%-11.80%-9.39%11/14/2025 (Estimated)Latest SLGL, CHEK, DRCT, and CAPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025SLGLSol-Gel Technologies-$0.67$4.17+$4.84$4.17$2.86 million$17.26 million8/11/2025Q2 2025CAPRCapricor Therapeutics-$0.48-$0.57-$0.09-$0.57$2.60 millionN/A8/5/2025Q2 2025DRCTDirect Digital-$0.96-$0.23+$0.73-$0.23$11.84 million$10.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/ACHEKCheck-CapN/AN/AN/AN/AN/ADRCTDirect DigitalN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A4.374.37CHEKCheck-CapN/A0.150.15DRCTDirect DigitalN/A0.490.49SLGLSol-Gel TechnologiesN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%CHEKCheck-Cap1.07%DRCTDirect Digital4.02%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics10.50%CHEKCheck-Cap0.48%DRCTDirect Digital62.82%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor Therapeutics10145.72 million40.92 millionOptionableCHEKCheck-Cap805.85 million5.82 millionNot OptionableDRCTDirect Digital6022.52 million8.37 millionNot OptionableSLGLSol-Gel Technologies502.79 million933,000OptionableSLGL, CHEK, DRCT, and CAPR HeadlinesRecent News About These CompaniesSol-Gel Technologies (NASDAQ:SLGL) Upgraded to Buy at Wall Street ZenSeptember 15 at 2:55 AM | marketbeat.comSol-Gel Technologies (NASDAQ:SLGL) Upgraded to "Buy" at Wall Street ZenSeptember 14 at 3:55 AM | americanbankingnews.comSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 36.6% in AugustSeptember 8, 2025 | marketbeat.comSol-Gel Announces Health Canada Approval of EPSOLAY®September 4, 2025 | finance.yahoo.comSol-Gel Technologies announces Health Canada approval of EPSOLAYSeptember 4, 2025 | msn.comSol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 240% return over the last yearSeptember 4, 2025 | finance.yahoo.comSol Gel Technologies trading halted, volatility trading pauseAugust 22, 2025 | msn.comSol-Gel Stock Delivers Over 150% Gain - Can The Upcoming Q4 Clinical Data Readout Sustain The Rally? August 21, 2025 | rttnews.comSol-Gel Technologies Reports Strong Q2 2025 ResultsAugust 20, 2025 | msn.comSol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 15, 2025 | globenewswire.comSol-Gel Technologies Ltd. (SLGL) Stock Price Today - WSJJuly 25, 2025 | wsj.comSol-Gel Technologies Ltd. (SLGL) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comSLGL Sol-Gel Technologies Ltd. - Seeking AlphaJune 26, 2025 | seekingalpha.comSol-Gel Technologies LtdJune 21, 2025 | morningstar.comMSol Gel Tech Stock Price HistoryJune 1, 2025 | investing.comSol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | finanznachrichten.deSol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays PessimisticMay 23, 2025 | msn.comSol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D ExpensesMay 23, 2025 | quiverquant.comQSol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | globenewswire.comInsider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of SharesMay 3, 2025 | uk.finance.yahoo.comThis Sol-Gel Technologies Insider Increased Their Holding In The Last YearMay 2, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLGL, CHEK, DRCT, and CAPR Company DescriptionsCapricor Therapeutics NASDAQ:CAPR$6.04 -0.32 (-5.03%) Closing price 04:00 PM EasternExtended Trading$6.14 +0.09 (+1.57%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Check-Cap NASDAQ:CHEK$2.12 +1.37 (+184.22%) Closing price 04:00 PM EasternExtended Trading$2.64 +0.52 (+24.34%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.Direct Digital NASDAQ:DRCT$0.42 0.00 (-0.50%) Closing price 04:00 PM EasternExtended Trading$0.42 +0.00 (+0.50%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.Sol-Gel Technologies NASDAQ:SLGL$23.96 -0.86 (-3.45%) Closing price 03:59 PM EasternExtended Trading$23.96 0.00 (0.00%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
